Stephen Andrew Welch
EVP & Head of Spec Generics · Keenova Therapeutics plc
- 2025
- Nov 12, 2025
- 2
Summary
Latest filing:
Stephen Andrew Welch has 2 SEC Form 4 filings on record, most recently on 12 November 2025.
Trading pattern
InsiderAlpha's records for Stephen Andrew Welch go back to 2025: 2 primary Form 4 filings, an average of 1.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Most active insiders across the market
Stephen Andrew Welch has no co-filers on record, so these are insiders with the largest open-market activity across the market in the last 90 days.
- NIPPON LIFE INSURANCE CO - $194.45M in CRBG purchases and sales in the last 90 days
- Paul R. Vigano - $192.63M in AVAH purchases and sales in the last 90 days
- Robert M. Williams Jr. - $192.63M in AVAH purchases and sales in the last 90 days
- Sean Lie - $192.09M in CBRS purchases and sales in the last 90 days
- August J. Troendle - $190.85M in MEDP purchases and sales in the last 90 days
- Mauad Bruno Sousa - $189.07M in AUGO purchases and sales in the last 90 days
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Stephen Andrew Welch?
Stephen Andrew Welch is a corporate insider, tracked as EVP & Head of Spec Generics. InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Stephen Andrew Welch last file a Form 4?
The most recent primary Form 4 on record is dated 12 November 2025, one of 2 filings going back to 2025.
Learn more
No Form 4 transactions on record for Stephen Andrew Welch yet.
Filings appear here automatically as they arrive from SEC EDGAR.